January 26, 2024
MISSISSAUGA, Ontario, Canada — HOYA Vision Care is releasing a new Canadian public awareness campaign geared towards highlighting the benefits of MiYOSMART spectacle lenses for children with myopia. The campaign will drive awareness about the short- and long-term impacts of myopia progression among children.
In an effort to better engage Canadian eye care professionals, HOYA will host an on-demand webinar in early 2024, offering ECPs the opportunity to hear from leading voices on myopia management, best practices for treatment, and practical information about setting up clinics to effectively treat myopia in children. In addition to attending industry trade shows, HOYA will increase its focus on supporting new opticians and graduates in the field of optometry throughout the year.
Additionally, in 2024, HOYA Canada will build on the successful launches of its MiYOSMART Chameleon photochromic and Sunbird polarized lenses in 2023 by expanding MiYOSMART’s availability.
“As myopia management becomes more mainstream and we see more treatment options hitting the market, it becomes more important than ever for ECPs to be savvy and look for sound evidence when choosing the right treatments for their patients,” said Kim Kochendorfer, Manager of Professional Affairs at HOYA Vision Care Canada.
“The window of time that we have to make the most impact on a child’s myopia progression is very narrow,” said Debbie Jones, clinical professor at the School of Optometry and Vision Science and a lead clinical scientist at the University of Waterloo with a focus on pediatric optometry. “This is why we need to treat early with treatments that have strong evidence.”
Across Canada and globally, HOYA Vision Care is committed to evidence-based myopia management and strives to bring this approach to the next level by empowering eye care professionals in their clinical practices. Its new Confidence Through Evidence campaign aims to educate ECPs about the importance of robust evidence in childhood myopia and bring attention to the 25+ scientific publications supporting MiYOSMART as the leading way to confidently manage myopia in their everyday clinical practice.
Most recently, HOYA Vision Care’s Global Medical Affairs team launched a three-year observational study in the United Kingdom to extend the reach of MiYOSMART benefits to European children with myopia. The study reached its one-year milestone earlier this year, and the results were presented at the Association for Research in Vision and Ophthalmology (ARVO) conference in New Orleans, Louisiana.1 Preliminary results of the study have demonstrated similar effectiveness of MiYOSMART spectacle lenses in Caucasian versus Asian children, particularly in children ages 8 to 13 years.1, 2 Most children were symptom-free within one week, showing great tolerability and acceptance.1
The efficacy of MiYOSMART spectacle lenses, proven by a wide spectrum of evidence, has resulted in over five million MiYOSMART spectacle lenses having been purchased by parents across the world between its launch in 2018 and August 2023.3
*MiYOSMART spectacle lenses have not been approved for use in the management of myopia in all countries, including the U.S., and are not currently available for sale in all countries, including the U.S.
References
1 2-Year Multi-Site Observational Study of MiYOSMART myopia control spectacle lenses in UK children:1-year results (2023)
2 Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. (2020)
3 Based on number of MiYOSMART spectacle lenses sold per HOYA sales data on file as of August 2023.
